Health

Ozempic Muscle Loss Fuels U.S. Drug Pipeline Race

Pharma giants eye billion-dollar market as GLP-1 side effects demand new fixes

By Oliver Walsh Jun 9, 2026 1 min read Updated: Jun 9, 2026

At a Glance

Ozempic's association with muscle loss is driving increased research.
Pharmaceutical companies are rapidly developing alternative medications.
This trend highlights a growing concern about GLP-1 receptor agonists.

Our Take

The story reveals a competitive surge in drug development following emerging evidence of muscle loss linked to Ozempic. This race underscores a critical focus on potential side effects and alternative therapies within the expanding GLP-1 market.

How do you feel about this?

Oliver Walsh

Health & Climate

Oliver Walsh analyses medical research, US health policy and climate science.